Inflammatory cytokine network in schizophrenia

World Journal of Biological Psychiatry

Volumn 15, Issue 3, 2014, Pages 174-187

  Zakharyan, Roksana ^a   Boyajyan, Anna ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Armenia)

Author keywords

Association; Cytokines; Genetic variants; Levels; Schizophrenia

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CHEMOKINE; COMPLEMENT FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GENETIC VARIABILITY; HUMAN; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULITIS;

CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; SCHIZOPHRENIA;

EID: 84896802583     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2013.830774     Document Type: Review

References (202)

1. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. 2008. Systematic metaanalyses and fi eld synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet 40: 827-834. (Pubitemid 351913655)
2. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Lopez-Rodriguez R, Fernandez-Navarro P, et al. 2011. ATA homozygosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Med Genet 12: 81.
3. Anderson G, Maes M. 2013. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 42: 5-19.
4. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'Osso B, et al. 2013. Immuno-infl ammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42: 1-4.
5. Arakelyan A, Zakharyan R, Khoyetsyan A, Poghosyan D, Aroutiounian R, Mrazek F, et al. 2011. Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia. BMC Clin Pathol 11: 10.
6. Arrode-Brusés G, Brusés JL. 2012. Maternal immune activation by poly(I:C) induces expression of cytokines IL-1 β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinfl ammation 9, 83.
7. Aston C, Jiang L, Sokolov BP. 2004. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77: 858-866. (Pubitemid 39187068)
8. Baker I, Masserano J, Wyatt RJ. 1996. Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 20: 199-203. (Pubitemid 26387520)
9. Barak V, Barak Y, Levine J, Nisman B, Roisman I. 1995. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6: 61-69.
10. Bauer K, Kornhuber J. 1987. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 236: 257-259. (Pubitemid 17130316)
11. Bernstein HG, Steiner J, Bogerts B. 2009. Glial cells in schizophrenia: pathophysiological signifi cance and possible consequences for therapy. Expert Rev Neurother 9: 1059-1071.
12. Bessis A, Bechade C, Bernard D, Roumier A. 2007. Microglial control of neuronal death and synaptic properties. Glia 55: 233-238. (Pubitemid 46225955)
13. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. 1995. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38: 297-302.
14. Bitzer-Quintero OK, González-Burgos I. 2012. Immune system in the brain: a modulatory role on dendritic spine morphophysiology? Neural Plast 2012: 348642.
15. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. 2001. Association between-G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 6: 79-82. (Pubitemid 32096069)
16. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, et al. 2012. Elevated serum level of type-2 cytokine and low IL-17 in fi rst episode psychosis and schizophrenia in relapse. J Psychiatr Res 46: 1421-1426.
17. Boyajyan A, Khoyetsyan A, Tsakanova G, Sim RB. 2008. Cryoglobulins as indicators of upregulated immune response in schizophrenia. Clin Biochemistry 41: 355-360.
18. Boyajyan AS, Khoyetsyan AG, Chavushyan AS. 2010. Alternative complement pathway in schizophrenia. Neurochem Res 35: 894-898.
19. Boyajyan A, Zakharyan R, Khoyetsyan A. 2012. Chapter XI. Molecular and genetic indicators of aberrant immunity and apoptosis in schizophrenia In: Sumiyoshi T, editor. Schizophrenia research: Recent advances. Section II: Neuropsychobiological insights, Series: Mental Illnesses and Treatments. USA: Nova Science Publishers Inc. p. 183-240.
20. Brites D, Fernandes A, Falcão AS, Gordo AC, Silva RF, Brito MA. 2009. Biological risks for neurological abnormalities associated with hyperbilirubinemia. J Perinatol 29 (Suppl 1): 8-13.
21. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et al. 2004. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161: 889-895. (Pubitemid 38625343)
22. Cazzullo CL, Saresella M, Roda K, Calvo MG, Bertrando P, Doria S, et al. 1998. Increased levels of CD8 and CD4 45RA lymphocytes in schizophrenic patients. Schizophr Res 31: 49-55. (Pubitemid 28234344)
23. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M, et al. 2002. Cytokine profi les in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26: 33-39. (Pubitemid 34045143)
24. Chavarria A, Alcocer-Varela J. 2004. Is damage in central nervous system due to infl ammation? Autoimmun Rev 3: 251-260. (Pubitemid 38887620)
25. Chen C, Tan B, Zhou Y, Zhou J, He Y, Li S, et al. 2012a. IL-28B genetic variant is associated with the risk of schizophrenia in the Chinese Han population. DNA Cell Biol 31: 988-992.
26. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, et al. 2012b. Infl ammation in patients with schizophrenia: the therapeutic benefi ts of risperidone plus add-on dextromethorphan . J Neuroimmune Pharmacol 7: 656-664.
27. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, et al. 1998. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12: 1327-1332. (Pubitemid 28330725)
28. Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, Pelayo-Terán JM, Fernandez-Prieto L, Leyva-Cobián F, et al. 2008. Interleukin-12 plasma levels in drug-na ï ve patients with a fi rst episode of psychosis: effects of antipsychotic drugs. Psychiatry Res 158: 206-216.
29. Cross AK, Woodroofe MN. 2001. Immunoregulation of microglial functional properties. Microsc Res Tech 54: 10-17. (Pubitemid 32537329)
30. Danis VA, Millington M, Hyland VJ, Grennan D. 1995. Cytokine production by normal human monocytes: Intersubject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 99: 303-310.
31. Dean B. 2009. Is schizophrenia the price of human central nervous system complexity? Aust NZ J Psychiatry 43: 13-24.
32. Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S, et al. 2009. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 16: 2965-2976.
33. Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang YP. 2013. Lack of association of IL-6 (-174 G/C) and TNF-α (-238 G/A) variants with paranoid schizophrenia in Indian Bengalee population . Cytokine 61: 455-458.
34. Dennison U, McKernan D, Cryan J, Dinan T. 2012. Schizophrenia patients with a history of childhood trauma have a proinfl ammatory phenotype. Psychol Med 42: 1865-1871.
35. Deverman BE, Patterson PH. 2009. Cytokines and CNS development . Neuron 64: 61-78.
36. Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, et al. 2013. Serum and gene expression profi le of cytokines in fi rst-episode psychosis. Brain Behav Immun 31: 92-95.
37. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. 2007. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93: 261-265. (Pubitemid 46817966)
38. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, et al. 2013. C-reactive protein is elevated in schizophrenia . Schizophr Res 143: 198-202.
39. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. 2009. Neuroinfl ammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50: 1801-1807.
40. Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, et al. 2010. The mononuclear phagocyte system and its cytokine infl ammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10: 59-76.
41. Duan S, Xu Y, Chen W, Liu Z, Guo T, Gao J, et al. 2004. No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population. Neurosci Lett 366: 139-143. (Pubitemid 38970143)
42. Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, et al. 2013. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub 25: 55-61.
43. Ebrinç S, Top C, Oncül O, Baolu C, Cavulu S, Cetin M. 2002. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. J Int Med Res 30: 314-317. (Pubitemid 34823310)
44. El-Mallakh RS, Suddath RL, Wyatt RJ. 1993. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17: 383-391. (Pubitemid 23096382)
45. Erbagci AB, Herken H, Köylüoglu O, Yilmaz N, Tarakçioglu M. 2001, Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Infl amm 10, 109-115. (Pubitemid 32735303)
46. Fatjó-Vilas M, Pomarol-Clotet E, Salvador R, Monté GC, Gomar JJ, Sarró S, et al. 2012. Effect of the interleukin-1 β gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study. Biol Psychiatry 72: 758-765.
47. Fawzi MH, Fawzi MM, Fawzi MM, Said NS. 2011. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190: 91-97.
48. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, et al. 2004. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 25: 1169-1173. (Pubitemid 39094019)
49. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, et al. 2009. Metabolic profi le of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194: 434-438.
50. Fila-Danilow A, Kucia K, Kowalczyk M, Owczarek A, Paul-Samojedny M, Borkowska P, et al. 2012. Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach. Mol Biol Rep 39: 7941-7947.
51. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. 2013. Increased infl ammatory markers identifi ed in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18: 206-214.
52. Francesconi LP, Ceresér KM, Mascarenhas R, Stertz L, Gama CS, Belmonte-de-Abreu P. 2011. Increased annexin-V and decreased TNF-α serum levels in chronic-medicated patients with schizophrenia. Neurosci Lett 502: 143-146.
53. Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, et al. 2010. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res 176: 99-102.
54. Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. 1997. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247: 228-233. (Pubitemid 27399827)
55. Gaillard JM, Tissot R. 1979. Blood-brain movements of tryptophan and tyrosine in manic-depressive illness and schizophrenia . J Neural Transm Suppl 15: 189-196.
56. Ganguli R, Rabin BS, Belle SH. 1989. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26: 427-430. (Pubitemid 19198231)
57. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. 1992. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 44: 113-123. (Pubitemid 23016248)
58. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS. 1994. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51: 1-10. (Pubitemid 24056866)
59. Gattaz WF, Dalgalarrondo P, Schröder HC. 1992. Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 6: 237-241.
60. Hacker UT, Erhardt S, Tschöp K, Jelinek T, Endes S. 2001. In fl uence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1b after live yellow fever vaccination. Clin Exp Immunol 125: 465-469. (Pubitemid 34155444)
61. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98: 4746-4751. (Pubitemid 32295047)
62. Hakobyan SS. 2005. Immune complexes and classical pathway of complement activation in schizophrenia. PhD thesis in biological sciences (molecular and cellular biology, 03.00.03; immunology, 03.00.06), Yerevan.
63. Hakobyan S, Boyajyan A, Sim RB. 2005. Classical pathway complement activity in schizophrenia. Neurosci Lett 374: 35-37. (Pubitemid 41556543)
64. Hänninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, et al., 2008, Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci, 258, 10-15. (Pubitemid 351208244)
65. Hanson DR, Gottesman II. 2005. Theories of schizophrenia: a genetic-infl ammatory-vascular synthesis. BMC Med Genet 6: 7.
66. Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. 2007. Variations in oligodendrocyte-related gene expression across multiple cortical regions: Implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 10: 565-573. (Pubitemid 46985258)
67. Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U. 2011. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45: 1358-1365.
68. Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. 2009. Similar immune profi le in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 11: 726-734.
69. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. 2011. Affective symptoms are associated with markers of infl ammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 45: 1608-1616.
70. Huang HH, Wang YC, Wu CL, Hong CJ, Bai YM, Tsai SJ, et al. 2011. TNF-α-308 G A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neurosci Lett 504: 277-280.
71. Hulkkonen J, Laippala P, Hurme M. 2000. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1b plasma levels in healthy individuals. Eur Cytokine Netw 11: 251-255.
72. Hurme M, Santtila S. 1998. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1b genes. Eur J Immunol 28: 2598-2602. (Pubitemid 28362734)
73. Igue R, Potvin S, Bah R, Stip E, Bouchard RH, Lipp O, et al. 2011. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 35: 1695-1698.
74. Ishizuka K, Kimura T, Igata R, Katsuragi S, Takamatsu J, Miyakawa T. 1997. Identi fi cation of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer ' s disease. Psychiatry Clin Neurosci 51: 135-138. (Pubitemid 27262094)
75. Iwamoto K, Kato T. 2006. Gene expression pro fi ling in schizophrenia and related mental disorders. Neuroscientist 12: 349-361. (Pubitemid 44050863)
76. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, et al. 2005. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 25: 5376-5381. (Pubitemid 40770917)
77. Jarskog LF. 2006. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr Opin Psychiatry 19: 307-312. (Pubitemid 44309490)
78. John GR, Lee SC, Brosnan CF. 2003. Cytokines: powerful regulators of glial cell activation. Neuroscientist 9: 10-22. (Pubitemid 36139575)
79. Jonakait GM. 1996. Cytokines in neuronal development. Adv Pharmacol 37: 35-36.
80. Jun TY, Lee KU, Pae CU, Chae JH, Bahk WM, Kim KS, Han H. 2003. Polymorphisms of interleukin-4 promoter and receptor gene for schizophrenia in the Korean population. Psychiatry Clin Neurosci 57: 283-288. (Pubitemid 36644414)
81. Kamińska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szersze M. 2001. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 49: 439-445. (Pubitemid 33622424)
82. Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, et al. 2005. Interaction of tumor necrosis alpha-G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 255: 279-283. (Pubitemid 41187037)
83. Katila H, Appelberg B, Hurme M, Rimón R. 1994a. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 12: 29-34. (Pubitemid 24135492)
84. Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimón R. 1994b. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 30: 20-23. (Pubitemid 24211368)
85. Katila H, Hänninen K, Hurme M. 1999. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 4: 179-181. (Pubitemid 29163981)
86. Kato T, Monji A, Hashioka S, Kanba S. 2007. Risperidone signifi cantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res 92: 108-115. (Pubitemid 46561234)
87. Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, et al. 2011. Anti-Infl ammatory properties of antipsychotics via microglia modulations: are antipsychotics a ' fi re extinguisher ' in the brain of schizophrenia? Mini Rev Med Chem 11: 565-574.
88. Khandaker GM, Zimbron J, Lewis G, Jones PB. 2012. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 16: 1-19.
89. Khoyetsyan A, Boyajyan A, Melkumova M. 2007. Level and chemical composition of cryoglobulins in schizophrenia. In: Brilliant Light in Life and Material Sciences. NATO Security through Science Series. Netherlands: Springer. p. 295-298.
90. Khoyetsyan A, Boyajyan A, Tsakanova G, Sim RB. 2008. Abnormal immune complexes in schizophrenia. Neurochem J 2: 329-330.
91. Kim YK, Lee MS, Suh KY. 1998. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 43: 701-704. (Pubitemid 28222392)
92. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. 2009. Cytokine changes and tryptophan metabolites in medication-na ï ve and medication-free schizophrenic patients. Neuropsychobiology 59: 123-129.
93. Kinney DK, Hintz K, Shearer EM, Barch DH, Riffin C, Whitley K, et al. 2010. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazars, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses 74: 555-563.
94. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. 2001. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia . Schizophr Res 50: 169-175. (Pubitemid 32595666)
95. Kraft AD, Harry GJ. 2011. Features of microglia and neuroinfl ammation relevant to environmental exposure and neurotoxicity . Int J Environ Res Public Health 8: 2980-3018.
96. Kubistova A, Horacek J, Novak T. 2012. Increased interleukin-6 and tumor necrosis factor alpha in fi rst episode schizophrenia patients versus healthy controls. Psychiatr Danub 24 (Suppl 1): 153-156.
97. Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. 2011. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro-and anti-infl ammatory balance. Rev Bras Psiquiatr 33: 268-274.
98. Kushner I. 1993. Regulation of the acute phase response by cytokines. Perspect Biol Med 36: 611-622.
99. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. 1993. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150: 1408-1410. (Pubitemid 23259579)
100. Lin CC, Chang CM, Chang PY, Huang TL. 2011. Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J 34: 375-81.
101. Liu J, Liu J, Zhou Y, Li S, Li Y, Song X, et al. 2011.Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol 30: 913-917.
102. Liu L, Jia FJ, Li HF. 2007. The mRNA expression levels of IL-1beta, TNF-alpha and tyrosine hydroxylase in peripheral blood of paranoid schizophrenic patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23: 1043-1105.
103. Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H, Fang C. 2010. Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 176: 1-7.
104. Löffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K. 2010. Clozapine mobilizes CD34 hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol 30: 591-595.
105. Looney JM, Childs HM. 1934. The lactic acid and glutathione content of the blood of schizophrenic patients. J Clin Invest 13: 963-968.
106. Maes M, Meltzer HY, Bosmans E. 1994. Immune-infl ammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89: 346-351. (Pubitemid 24157957)
107. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. 1995a. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29: 141-152.
108. Maes M, Meltzer HY, Buckley P, Bosmans E. 1995b. Plasmasoluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244: 325-329.
109. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, et al. 1996. Lower plasma CC16, a natural antiinfl ammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 21: 39-50. (Pubitemid 26291899)
110. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. 1997. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66: 1-11. (Pubitemid 27111375)
111. Maric NP, Svrakic DM. 2012. Why schizophrenia genetics needs epigenetics: a review. Psychiatr Danub 24: 2-18.
112. Mayilyan KR. 2012. Complement genetics, defi ciencies, and disease associations. Protein Cell 3: 487-496.
113. Mayilyan KR, Arnold JN, Presanis JS, Soghoyan AF, Sim RB. 2006. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 404: 336-341. (Pubitemid 44108442)
114. Mayilyan KR, Dodds AW, Boyajyan AS, Soghoyan AF, Sim RB. 2008a. Complement C4B protein in schizophrenia. World J Biol Psychiatry 9: 225-230.
115. Mayilyan KR, Weinberger DR, Sim RB. 2008b. The complement system in schizophrenia. Drug News Perspect 21(4): 200-210.
116. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. 1995. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152: 1291-1297.
117. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr, et al. 2005. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112: 1113-1120. (Pubitemid 41216117)
118. Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leinsinger G, et al. 2001. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry 158: 1316-1319. (Pubitemid 32717709)
119. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. 2009. Infl ammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66: 1013-1022.
120. Meyer U. 2011. Anti-infl ammatory signaling in schizophrenia. Brain Behav Immun 25: 1507-1518.
121. Meyer U, Feldon J, Yee BK. 2009. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35(5): 959-972.
122. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70: 663-671.
123. Miller BJ, Culpepper N, Rapaport MH. 2013. C-reactive protein levels in schizophrenia. Clin Schizophr Relat Psychoses 1-22. [Epub ahead of print].
124. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N, et al. 2011. Stress and infl ammation reduce brain-derived neurotrophic factor expression in fi rst-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 72: 1677-1684.
125. Monji A, Kato T, Kanba S. 2009. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63: 257-265.
126. Monteleone P, Fabrazzo M, Tortorella A, Maj M. 1997. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71: 11-17. (Pubitemid 27304310)
127. Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB. 2007. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B: 318-324. (Pubitemid 46642021)
128. Müller N, Schwarz M. 2006. Schizophrenia as an infl ammationmediated dysbalance of glutamatergic neurotransmission. Neurotox Res, 10, 131-148.
129. Müller N, Schwarz MJ. 2007. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl, 72, 269-280.
130. Müller N, Riedel M, Ackenheil M, Schwarz MJ., 2000, Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry, 1, 173-179.
131. Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, Montresor C, Gennarelli M. 2005. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet 132B: 1-4. (Pubitemid 40066185)
132. Murray CJL, Lopez AD, eds. 1996. Summary: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press.
133. Naudin J, Mège JL, Azorin JM, Dassa D. 1996. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20: 269-273. (Pubitemid 26232971)
134. Nawa H, Takahashi M, Patterson PH. 2000. Cytokine and growth factor involvement in schizophrenia-support for the developmental model. Mol Psychiatry 5: 594-603.
135. Naz M, Riaz M, Saleem M. 2011. Potential role of neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 38: 4709-4714.
136. Ng F, Berk M, Dean O, Bush AI. 2008. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11: 851-876.
137. Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, et al. 2013. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J Psychiatr Res 47: 467-471.
138. Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, et al. 2000. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer ' s disease and Parkinson ' s disease. Psychiatry Clin Neurosci 54: 419-426.
139. Pae CU, Chung KI, Kim JJ, Yu HS, Lee CU, Lee SJ, et al. 2004a. Monocyte chemoattractant protein-1 promoter-2518 polymorphism and schizophrenia in the Korean population. Psychiatr Genet 14: 65-67.
140. Pae CU, Lee KU, Han H, Serretti A, Jun TY. 2004b. Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res 125: 65-68. (Pubitemid 38210254)
141. Pae CU, Serretti A, Artioli P, Kim TS, Kim JJ, Lee CU, et al. 2006. Interaction analysis between 5-HTTLPR and TNFA-238/-308 polymorphisms in schizophrenia. J Neural Transm 113: 887-897. (Pubitemid 43962782)
142. Palladino I, Salani F, Ciaramella A, Rubino IA, Caltagirone C, Fagioli S, et al. 2012. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J Neuroinfl ammation 9: 206.
143. Patterson PH. 2009. Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 204: 313-321.
144. Paul-Samojedny M, Owczarek A, Kowalczyk M, Suchanek R, Palacz M, Kucia K, et al. 2013. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNF α ) gene polymorphisms with paranoid schizophrenia in a Polish population . J Neuropsychiatry Clin Neurosci 25: 72-82.
145. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, et al. 2012. Similarities in serum oxidative stress markers and infl ammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46: 819-824.
146. Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J. 1992. A TaqI polymorphismin the human interleukin-1b (IL-1b) gene correlates with IL-1b secretion in vitro. Eur J Clin Invest 22: 396-402.
147. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. 2008. Infl ammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801-808. (Pubitemid 351410515)
148. Quan N and Herkenham M. 2002. Connecting cytokines and brain: A review of current issues. Histol Histopathol 17: 273-288. (Pubitemid 34116430)
149. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. 1997. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25(2): 123-129. (Pubitemid 27245134)
150. Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, et al. 2011. Dysregulation of chemocytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 12: 13.
151. Riedel M, Krönig H, Schwarz MJ, Engel RR, Kühn KU, Sikorski C, et al. 2002. No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia . Eur Arch Psychiatry Clin Neurosci 252: 232-234. (Pubitemid 36068385)
152. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, et al. 2007. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 31: 361-364. (Pubitemid 46209417)
153. Rudduck C, Beckman L, Franz é n G, Jacobsson L, Lindström L. 1998. Complement factor C4 in schizophrenia. Hum Hered 35(4): 223-226.
154. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. 2007. Infl ammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7: 46.
155. Saha N, Bhattacharyya SP, Tsoi WF. 1985. Serum protein markers in schizophrenia: haptoglobin, transferrin and group-specifi c component types. Singapore Med J 26: 337-340. (Pubitemid 16257476)
156. Santos Sória LD, Moura Gubert CD, Ceresér KM, Gama CS, Kapczinski F. 2012. Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy. Rev Bras Psiquiatr 34: 119-120.
157. Santtila S, Savinainen K, Hurme M. 1998. Presence of the IL-1RA allele 2 (IL1RN * 2) is associated with enhanced IL-1b production in vitro. Scand J Immunol 47: 195-198. (Pubitemid 28153395)
158. Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Iijima Y, et al. 2011a. Possible association between interleukin-1 gene and schizophrenia in a Japanese population. Behav Brain Funct 7: 35.
159. Sasayama D, Wakabayashi C, Hori H, Teraishi T, Hattori K, Ota M, et al. 2011b. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiatr Res 45: 1439-1444.
160. Schoknecht K, Shalev H. 2012. Blood-brain barrier dysfunction in brain diseases: clinical experience. Epilepsia 53: 7-13.
161. Schroers R, Nöthen MM, Rietschel M, Albus M, Maier W, Schwab S, et al. 1997. Investigation of complement C4B defi-ciency in schizophrenia. Hum Hered 47: 279-282. (Pubitemid 27434543)
162. Schwarz MJ, Krönig H, Riedel M, Dehning S, Douhet A, Spellmann I, et al. 2006. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256: 72-76.
163. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. 2002. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401. (Pubitemid 34158948)
164. Shcherbakova I, Neshkova E, Dotsenko V, Platonova T, Shcherbakova E, Yarovaya G. 1999. The possible role of plas kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 43: 273-279.
165. Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E, et al. 1991. Serum interleukin-6 in schizophrenic patients. Life Sci 49: 661-664.
166. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL. 2006. Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta. Schizophr Res 88: 235-244 (Pubitemid 44693237)
167. Singh B, Bera NK, Nayak CR, Chaudhuri TK. 2009. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 47: 1-5.
168. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. 2009. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65: 481-488.
169. Spivak B, Radwan M, Elimelech D, Baruch Y, Avidan G, Tyano S. 1989. A study of the complement system in psychiatric patients. Biol Psychiatry 26: 640-642. (Pubitemid 19244778)
170. Spivak B, Radwan M, Brandon J, Baruch Y, Stawski M, Tyano S, et al. 1993. Reduced total complement haemolytic activity in schizophrenic patients. Psychol Med 23: 315-318. (Pubitemid 23209225)
171. Stolp HB, Dziegielewska KM. 2009. Role of developmental infl ammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 35: 132-146.
172. Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, et al. 2004. Prefrontal abnormality of schizophrenia revealed by DNA microarray: Impact on glial and neurotrophic gene expression. Ann NY Acad Sci 1025: 84-91. (Pubitemid 39643849)
173. Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, et al. 2008. Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. Neurosci Lett 440: 35-37.
174. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T. 2006. Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann NY Acad Sci. 1088: 219-229. (Pubitemid 47092033)
175. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M. 2000. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res 96: 75-80.
176. Tandon R, Keshavan MS, Nasrallah HA. 2008. Schizophrenia, " just the facts " what we know in 2008. Schizophr Res 102: 1-18.
177. Tatsumi M, Sasaki T, Sakai T, Kamijima K, Fukuda R, Kunugi H, et al. 1997. Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: no evidence for the association or linkage. Am J Med Genet 74: 338-341. (Pubitemid 27251236)
178. Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, et al. 2008. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 710-714. (Pubitemid 351312370)
179. Turnbull AV, Rivier C. 1995. Regulation of the HPA axis by cytokines. Brain Behav Immun 9: 253-275. (Pubitemid 26039767)
180. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. 2008. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64: 820-822.
181. Van der Meide PH, Schellekens H. 1996. Cytokines and the immune response. Biotherapy 8: 243-249. (Pubitemid 26186223)
182. Vuksan-Cusa B, Sagud M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, et al. 2012. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia . Nord J Psychiatry [Epub ahead of print].
183. Walkup J, Gallagher SK. 1999. Schizophrenia and the life course: national fi ndings on gender differences in disability and service use. Int J Aging Hum Dev 49: 79-105. (Pubitemid 30017335)
184. Wan C, La Y, Zhu H, Yang Y, Jiang L, Chen Y, et al. 2007. Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids 32: 101-108. (Pubitemid 44866574)
185. Wang JF, Shao L, Sun X, Young LT. 2009. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11: 523-529.
186. Watanabe Y, Nunokawa A, Shibuya M, Kaneko N, Nawa H, Someya T. 2008. Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population. Eur Arch Psychiatry Clin Neurosci 258: 422-427.
187. Watanabe Y, Someya T, Nawa H. 2010. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 64: 217-230.
188. Wigmore SJ, Fearon KCH, Maingay JP, Lai PBS, Ross JA. 1997. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 273: E720-726.
189. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H. 1996. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 279-284. (Pubitemid 26252546)
190. Wong CT, Tsoi WF, Saha N. 1996. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 22: 165-171. (Pubitemid 26394564)
191. Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. 2006. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78: 3571-3576. (Pubitemid 43848947)
192. Yang ZW, Chengappa KN, Shurin G, Brar JS, Rabin BS, Gubbi AV, et al. 1994. An association between antihippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol Med 24: 449-455. (Pubitemid 24158857)
193. Yarlagadda A, Hampe CS, Clayton AH. 2010. The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia . Psychiatry (Edgmont) 7: 20-23.
194. Yoshida M, Shiroiwa K, Mouri K, Ishiguro H, Supriyanto I, Ratta-Apha W, et al. 2012. Haplotypes in the expression quantitative trait locus of interleukin-1 β gene are associated with schizophrenia. Schizophr Res 140: 185-191.
195. Zakharyan R, Khoyetsyan A, Arakelyan A, Boyajyan A, Gevorgyan A, Stahelova A, et al. 2010. Association of C1QB gene polymorphism with schizophrenia in Armenian population . BMC Med Genet 12: 126.
196. Zakharyan R, Boyajyan A, Arakelyan A, Melkumova M, Mrazek F, Petrek M. 2012a. Monocyte chemoattractant protein-1 in schizophrenia:-2518A/G genetic variant and protein levels in Armenian population. Cytokine 58: 351-354.
197. Zakharyan R, Petrek M, Arakelyan A, Mrazek FAtshemyan S, Boyajyan A. 2012b. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 80: 136-142.
198. Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura GB, Rossi G, et al. 2003. Association between IL-1beta-511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. J Psychiatr Res 37: 457-462. (Pubitemid 37243013)
199. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. 2002. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology . Schizophr Res 57: 247-258. (Pubitemid 35240027)
200. Zhong H, Peng L, Zhu Y, Dang J, Huo Z. 2011. Association of the polymorphisms in the promoter region of tumor necrosis factor alpha and interleukin 6 genes with schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28: 427-431.
201. Zhong HJ, Peng L, Zhu YS, Dang J, Huo ZH. 2011. Association of the polymorphisms in the promoter region of tumor necrosis factor alpha and interleukin 6 genes with schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28: 427-431.
202. Zubarev OE, Klimenko VM. 2011. Elevation of proinfl ammatory cytokines level at early age as the risk factor of neurological and mental pathology development. Ross Fiziol Zh Im I M Sechenova 97: 1048-1059.